Anna Bershteyn

Anna Bershteyn

Auto-generated profile, based on publicly available information

Anna Bershteyn

New York University Grossman School of Medicine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Pathogens and Disease
Verified
Journal Article
Open access
PDF file
ABAnna Bershteyn
Anna Bershteyn
JGJaline Gerardin
Jaline Gerardin
DBDaniel Bridenbecker
Daniel Bridenbecker
CLChristopher W Lorton
Christopher W Lorton
JBJonathan Bloedow
Jonathan Bloedow
FMfor the Institute for Disease Modeling
for the Institute for Disease Modeling
Individual-based models provide modularity and structural flexibility necessary for modeling of infectious diseases at the within-host and population levels, but are challenging to implement. Levels of complexity can exceed the capacity and timescales for students and trainees in most academic institutions. Here we describe the process and advantages of a multi-disease framework approach developed with formal software support. The epidemiological modeling software, EMOD, has undergone a decade of software development. It is structured so that a majority of code is shared across disease modeling including malaria, HIV, tuberculosis, dengue, polio and typhoid. In additional to implementation efficiency, the sharing increases code usage and testing. The freely available codebase also includes hundreds of regression tests, scientific feature tests and component tests to help verify functionality and avoid inadvertent changes to functionality during future development. Here we describe the levels of detail, flexible configurability and modularity enabled by EMOD and the role of software development principles and processes in its development.

1 March 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
RBRuanne V Barnabas
Ruanne V Barnabas
EBElizabeth R Brown
Elizabeth R Brown
ABAnna Bershteyn
Anna Bershteyn
HKHelen C Stankiewicz Karita
Helen C Stankiewicz Karita
CJChristine Johnston
Christine Johnston
JBJared M Baeten
Jared M Baeten
Clinical trials have ruled out a role of hydroxychloroquine in the treatment of COVID-19, but it has been hypothesized that hydroxychloroquine's activity against SARS-CoV-2 in the laboratory sugges... Visual Postexposure Hydroxychloroquine Prophylaxis to Prevent SARS-CoV-2 Infection Clinical trials have ruled out a role of hydroxychloroquine in the treatment of COVID-19, but it has been... Background: Effective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strat...

9 July 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AAAdam Akullian
Adam Akullian
AVAlain Vandormael
Alain Vandormael
JMJoel C. Miller
Joel C. Miller
ABAnna Bershteyn
Anna Bershteyn
EWEdward Wenger
Edward Wenger
FTFrank Tanser
Frank Tanser
Significance: HIV incidence has recently been in decline across some of the most intense epidemics in sub-Saharan Africa due to the scale-up of prevention and transmission-blocking treatments. Understanding whether declines in incidence are being felt equally across age and gender can help prioritize demographic groups where more effort is needed to lower transmission. We found that HIV incidence has declined disproportionately in the youngest men and women in a population with the highest HIV prevalence in the world. Shifts in the age distribution of risk may be the consequence of aging prevalence, prioritized prevention to younger individuals, and delays in age at infection from reduced overall force of infection. Our results highlight the need to expand age targets for HIV prevention.

1 May 2019 in Health & Place
Verified
Journal Article
Open access
CCCarol S. Camlin
Carol S. Camlin
AAAdam Akullian
Adam Akullian
Torsten B. NeilandsTorsten B. Neilands
Torsten B. Neilands
MGMonica Getahun
Monica Getahun
ABAnna Bershteyn
Anna Bershteyn
ECEdwin D. Charlebois
Edwin D. Charlebois
Mobility in sub-Saharan Africa links geographically-separate HIV epidemics, intensifies transmission by enabling higher-risk sexual behavior, and disrupts care. This population-based observational cohort study measured complex dimensions of mobility in rural Uganda and Kenya. Survey data were collected every 6 months beginning in 2016 from a random sample of 2308 adults in 12 communities across three regions, stratified by intervention arm, baseline residential stability and HIV status. Analyses were survey-weighted and stratified by sex, region, and HIV status. In this study, there were large differences in the forms and magnitude of mobility across regions, between men and women, and by HIV status. We found that adult migration varied widely by region, higher proportions of men than women migrated within the past one and five years, and men predominated across all but the most localized scales of migration: a higher proportion of women than men migrated within county of origin. Labor-related mobility was more common among men than women, while women were more likely to travel for non-labor reasons. Labor-related mobility was associated with HIV positive status for both men and women, adjusting for age and region, but the association was especially pronounced in women. The forms, drivers, and correlates of mobility in eastern Africa are complex and highly gendered. An in-depth understanding of mobility may help improve implementation and address gaps in the HIV prevention and care continua.

9 March 2020 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
DGDylan Green
Dylan Green
DTDiana M Tordoff
Diana M Tordoff
BKBrenda Kharono
Brenda Kharono
AAAdam Akullian
Adam Akullian
ABAnna Bershteyn
Anna Bershteyn
Paul DrainPaul Drain
Paul Drain
Introduction: Heterogeneity of sociodemographics and risk behaviours across the HIV treatment cascade could influence the public health impact of universal ART in sub‐Saharan Africa if those not virologically suppressed are more likely to be part of a risk group contributing to onward infections. Sociodemographic and risk heterogeneity across the treatment cascade has not yet been comprehensively described or quantified and we seek to systematically review and synthesize research on this topic among adults in Africa.Methods: We conducted a systematic review of peer‐reviewed literature in Embase and MEDLINE databases as well as grey literature sources published in English between 2014 and 2018. We included studies that included people living with HIV (PLHIV) aged ≥15 years, and reported a 90‐90‐90 outcome: awareness of HIV‐positive status, ART use among those diagnosed or viral suppression among those on ART. We summarized measures of association between sociodemographics, within each outcome, and as a composite measure of population‐wide viral suppression.Results and discussion: From 3533 screened titles, we extracted data from 92 studies (50 peer‐reviewed, 42 grey sources). Of included studies, 32 reported on awareness, 53 on ART use, 32 on viral suppression and 23 on population‐wide viral suppression. The majority of studies were conducted in South Africa, Uganda, and Malawi and reported data for age and gender. When stratified, PLHIV ages 15 to 24 years had lower median achievement of the treatment cascade (60‐49‐81), as compared to PLHIV ≥25 years (70‐63‐91). Men also had lower median achievement of the treatment cascade (66‐72‐85), compared to women (79‐76‐89). For population‐wide viral suppression, women aged ≥45 years had achieved the 73% target, while the lowest medians were among 15‐ to 24‐year‐old men (37%) and women (49%).Conclusions: Considerable heterogeneity exists by age and gender for achieving the HIV 90‐90‐90 treatment goals. These results may inform delivery of HIV testing and treatment in sub‐Saharan Africa, as targeting youth and men could be a strategic way to maximize the population‐level impact of ART.

9 August 2022 in The Lancet Global Health
Verified
Journal Article
Open access
ABAnna Bershteyn
Anna Bershteyn
LJLise Jamieson
Lise Jamieson
HKHae-Young Kim
Hae-Young Kim
IPIngrida Platais
Ingrida Platais
MMMasabho P Milali
Masabho P Milali
BNBrooke E Nichols
Brooke E Nichols
In this so-called treat-all era, antiretroviral therapy (ART) interruptions contribute to an increasing proportion of HIV infections and deaths. Many strategies to improve retention on ART cost more than standard of care. In this study, we aimed to estimate the upper-bound costs at which such interventions should be adopted. In this combined analysis, we compared the infections averted, disability-adjusted life-years (DALYs) averted, and upper-bound costs of interventions that improve ART retention in three HIV models with diverse structures, assumptions, and baseline settings: EMOD in South Africa, Optima in Malawi, and Synthesis in sub-Saharan African low-income and middle-income countries (LMICs). We modelled estimates over a 40-year time horizon, from a baseline of Jan 1, 2022, when interventions would be implemented, to Jan 1, 2062. We varied increment of ART retention (25%, 50%, 75%, and 100% retention), the extent to which interventions could be targeted towards individuals at risk of interrupting ART, and cost-effectiveness thresholds in each setting. Despite simulating different settings and epidemic trends, all three models produced consistent estimates of health benefit (ie, DALYs averted) and transmission reduction per increment in retention. The range of estimates was 1·35–3·55 DALYs and 0·12–0·20 infections averted over the 40-year time horizon per additional person-year retained on ART. Upper-bound costs varied by setting and intervention effectiveness. Improving retention by 25% among all people receiving ART, regardless of risk of ART interruption, gave an upper-bound cost per person-year of US$2–6 in Optima (Malawi), $43–68 in Synthesis (LMICs in sub-Saharan Africa), and $28–180 in EMOD (South Africa). A maximally targeted and effective retention intervention had an upper-bound cost per person-year of US$93–223 in Optima (Malawi), $871–1389 in Synthesis (LMICs in sub-Saharan Africa), and $1013–6518 in EMOD (South Africa). Upper-bound costs that could improve ART retention vary across sub-Saharan African settings and are likely to be similar to or higher than was estimated before the start of the treat-all era. Upper-bound costs could be increased by targeting interventions to those most at risk of interrupting ART. Bill & Melinda Gates Foundation.